NASDAQ:XCUR Exicure (XCUR) Stock Price, News & Analysis → Bigger Than NVIDIA? (From Behind the Markets) (Ad) Free XCUR Stock Alerts $0.33 0.00 (0.00%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$0.30▼$0.3550-Day Range$0.33▼$0.6252-Week Range$0.30▼$1.50Volume205,108 shsAverage Volume421,604 shsMarket Capitalization$2.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends Get Exicure alerts: Email Address Exicure MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy3.64% of Float Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews Sentiment0.62Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.05 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Exicure.Read more about Exicure's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.64% of the float of Exicure has been sold short.Short Interest Ratio / Days to CoverExicure has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Exicure has recently increased by 116.84%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldExicure does not currently pay a dividend.Dividend GrowthExicure does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExicure has received a 74.39% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for mental health", "Clinical research services for cancer", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Exicure is -0.67. Previous Next 2.6 News and Social Media Coverage News SentimentExicure has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Exicure this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Exicure to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exicure insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.40% of the stock of Exicure is held by insiders.Percentage Held by Institutions42.82% of the stock of Exicure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exicure's insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Exicure is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exicure is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExicure has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Exicure's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and finds hot stocks that you probably have never even heard of… …it recommends the best potential strategy to use on the names it finds (with historical data to prove it)Click Here To Read More About This Game Changing AI Tool About Exicure Stock (NASDAQ:XCUR)Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.Read More XCUR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XCUR Stock News HeadlinesJune 17 at 11:02 PM | investorplace.comXCUR Stock Earnings: Exicure Reported Results for Q1 2024June 17 at 4:01 PM | businesswire.comExicure, Inc. Reports First Quarter 2024 Financial ResultsJune 14, 2024 | americanbankingnews.comShort Interest in Exicure, Inc. (NASDAQ:XCUR) Grows By 116.8%June 6, 2024 | investorplace.comXCUR Stock Earnings: Exicure Reported Results for Q4 2023May 29, 2024 | msn.comWhy Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving PremarketMay 23, 2024 | finance.yahoo.comExicure, Inc. Received Nasdaq Notice of a Delisting DeterminationMay 23, 2024 | businesswire.comExicure, Inc. Received Nasdaq Notice of a Delisting DeterminationMay 18, 2024 | finance.yahoo.comExicure, Inc. (XCUR)May 16, 2024 | investorplace.comXCUR Stock Earnings: Exicure Reported Results for Q3 2023May 16, 2024 | finance.yahoo.comExicure, Inc. Reports Third Quarter 2023 Financial ResultsMay 16, 2024 | businesswire.comExicure, Inc. Reports Third Quarter 2023 Financial ResultsApril 24, 2024 | investing.comExicure faces Nasdaq non-compliance over delayed filingApril 22, 2024 | businesswire.comExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-KFebruary 22, 2024 | benzinga.comExicure Stock (NASDAQ:XCUR), Short Interest ReportFebruary 6, 2024 | benzinga.comWhy FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionFebruary 6, 2024 | msn.comWhy Palantir Technologies Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving PremarketFebruary 6, 2024 | msn.comExicure Inc Announces Licensing Patents for Therapeutic AdvancementFebruary 5, 2024 | marketwatch.comExicure, Bluejay Therapeutics Enter Patent License Agreement to Develop Hepatitis TreatmentFebruary 5, 2024 | finance.yahoo.comExicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of HepatitisFebruary 1, 2024 | msn.comBest Undervalued Stocks for February 2024December 16, 2023 | ca.finance.yahoo.comExicure, Inc. (XCUR) Stock Price, News, Quote & History - Yahoo FinanceDecember 8, 2023 | investorplace.comWhy Is Exicure (XCUR) Stock Up 57% Today?November 28, 2023 | msn.comExicure receives Nasdaq delinquency notice on late filing of its form 10-QNovember 9, 2023 | morningstar.comExicure Inc XCURAugust 29, 2023 | finance.yahoo.comLacklustre Performance Is Driving Exicure, Inc.'s (NASDAQ:XCUR) 25% Price DropSee More Headlines Receive XCUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exicure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/16/2024Today6/17/2024Next Earnings (Estimated)7/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XCUR CUSIPN/A CIK1698530 Webwww.exicuretx.com Phone(847) 673-1700FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,910,000.00 Net MarginsN/A Pretax Margin14.60% Return on Equity-212.40% Return on Assets-102.47% Debt Debt-to-Equity RatioN/A Current Ratio0.81 Quick Ratio0.81 Sales & Book Value Annual Sales$28.83 million Price / Sales0.10 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book0.93Miscellaneous Outstanding Shares8,650,000Free Float7,924,000Market Cap$2.81 million OptionableNot Optionable Beta1.28 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesMr. Paul Kang (Age 62)CEO & Director Mr. Joshua Miller (Age 48)Chief Accounting Officer Mr. Bart AndersonSenior Director of R&DKey CompetitorsImunonNASDAQ:IMNNElevai LabsNASDAQ:ELABVaccinexNASDAQ:VCNXAvalo TherapeuticsNASDAQ:AVTXMIRA PharmaceuticalsNASDAQ:MIRAView All CompetitorsInsidersCo. Ltd. DgpSold 3,400,000 sharesTotal: $4.49 M ($1.32/share)View All Insider Transactions XCUR Stock Analysis - Frequently Asked Questions How have XCUR shares performed in 2024? Exicure's stock was trading at $0.5803 at the beginning of the year. Since then, XCUR shares have decreased by 43.9% and is now trading at $0.3254. View the best growth stocks for 2024 here. Are investors shorting Exicure? Exicure saw a increase in short interest in May. As of May 31st, there was short interest totaling 274,300 shares, an increase of 116.8% from the May 15th total of 126,500 shares. Based on an average trading volume of 293,000 shares, the short-interest ratio is currently 0.9 days. Approximately 3.6% of the company's stock are short sold. View Exicure's Short Interest. When is Exicure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, July 12th 2024. View our XCUR earnings forecast. How were Exicure's earnings last quarter? Exicure, Inc. (NASDAQ:XCUR) issued its quarterly earnings data on Thursday, May, 16th. The company reported ($0.61) earnings per share (EPS) for the quarter. When did Exicure's stock split? Exicure's stock reverse split on Thursday, June 30th 2022. The 1-30 reverse split was announced on Thursday, June 30th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Exicure? Shares of XCUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XCUR) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages...Weiss Ratings | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exicure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.